The entire external analgesic category is up 6.7%, reaching a base of $486.9 million across total U.S. multi-outlets for the 52 weeks ended June 15, according to IRI data. And Salonpas, with a 10.9% dollar share, is helping to drive that growth with positive sales gains of 28.7% to $52.9 million.
The lion’s share of the analgesics business may be in internal analgesics — sales of which totaled $3.6 billion, up 1.1% for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI — but it’s alternative pain relievers that may represent the growth opportunity.
“It’s not enough to pull drowning victims out of the river. You have to walk upstream to find out who’s throwing them in.” Physician and educator David Kilgore invoked that piece of wisdom from Episcopal bishop V. Gene Robinson to describe the current state of medicine in the United States — and the steps needed to drag the nation’s outmoded, costly and inefficient healthcare system into the 21st century.
“We have a system that needs fixing.” That comment on the state of the nation’s healthcare system, shared by physician and New York Times correspondent and senior writer Elisabeth Rosenthal, served as the springboard for a high-level summit on the future of health care in the United States. The event drew a who’s who of nationally known health experts, scientists and government officials.
In July, the National Association of Specialty Pharmacy and the Specialty Pharmacy Association of America announced the two organizations would merge, creating the largest professional and trade association in the specialty pharmacy industry. To find out more,DSNinterviewed Larry Irene, CEO of Armada Health Care and SPAARx founder, and Gary Cohen, CEO of NASP.
“Leading change.” That was theme for this year’s Cardinal Health Retail Business Conference, held in Washington, D.C., last month at the Gaylord National Resort and Convention Center, from July 23 to 26.